RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo trial aims to close cancer care gap for minorities
Disease control Recruiting nowThis early-stage study tests whether giving two targeted drugs together is feasible for people with certain B-cell lymphomas that have returned or stopped responding to prior therapy. The drugs, zanubrutinib and sonrotoclax, work by blocking proteins that help cancer cells surviv…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:27 UTC
-
New drug duo shows promise for Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs—nivolumab, which helps the immune system attack cancer, and ASTX727, which targets abnormal cells—can shrink or stabilize B-cell lymphomas that have returned or stopped responding to standard treatments. About 32 adult…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
Radiation before CAR T-Cell therapy: a new hope for lymphoma patients?
Disease control Recruiting nowThis study tests whether giving radiation to all active cancer spots before CAR T-cell therapy can help people with large B-cell lymphoma that has returned or not responded to treatment. About 9 adults will receive targeted radiation to control the disease while their own immune …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
Vitamin c boost: could high doses make chemo work better for tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C to standard chemotherapy can help treat blood cancers like lymphoma and chronic myelomonocytic leukemia (CMML) that have returned or not responded to treatment. About 80 adults will receive the combination therapy. The goal is t…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:18 UTC
-
New combo therapy aims to boost remission in tough lymphoma cases
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive the combination therapy. The goa…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
Promising new combo therapy offers hope for lymphoma patients who Can't have transplants
Disease control Recruiting nowThis study is for people with a type of blood cancer (large B-cell lymphoma) that has come back or not gotten better after earlier treatments, and who cannot have a stem cell transplant. The trial tests whether adding either tazemetostat or zanubrutinib to a standard two-drug com…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 adults will receive the combination to find the safest dose and…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Experimental combo therapy aims to stop lymphoma relapse after transplant
Disease control Recruiting nowThis early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Engineered immune cells take on HIV-Linked lymphoma in new trial
Disease control Recruiting nowThis phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New Five-Drug cocktail shows promise for Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve complete …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a poop pill make cancer therapy work better?
Disease control Recruiting nowThis study tests whether a fecal transplant from healthy donors can repair gut damage caused by antibiotics and chemotherapy in lymphoma patients receiving CAR T-cell therapy. About 56 adults with relapsed or hard-to-treat lymphoma will be randomly assigned to get either the tran…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug duo shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs—loncastuximab tesirine and mosunetuzumab—can shrink or eliminate tumors in people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 36 adults will receive the drug combination, and…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Double punch: experimental drug may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug odronextamab before and after standard CAR-T cell therapy can help people with a type of aggressive lymphoma (DLBCL) that has returned or not responded to prior treatments. About 34 adults who have already tried at least two other therapie…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Can extra drugs boost CAR t success in tough lymphoma?
Disease control Recruiting nowThis study tests whether giving two additional drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy helps control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be rand…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New drug may boost CAR-T success in tough lymphomas
Disease control Recruiting nowThis study tests a drug called odronextamab given before CAR-T cell therapy for people with large B-cell lymphoma that has returned or not responded to treatment. The goal is to see if this approach can keep the cancer under control and help more patients successfully receive CAR…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo aims to outsmart tough lymphoma
Disease control Recruiting nowThis study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 04, 2026 16:23 UTC